Pharmaceuticals & Therapeutics

Bright Path Labs is using military-backed continuous-flow technology to reshore critical drug manufacturing, challenging the dominance of overseas APIs.

BridgeBio is using cultural icons to find undiagnosed heart disease in Black men. It’s a brilliant public health move—and a shrewd business strategy.

Alpha Cognition is set to present compelling real-world data on ZUNVEYL, revealing how this novel prodrug could reduce psychotropic use in long-term care.

As liver cancer deaths near 31,000 annually, a new House resolution and AI-driven blood tests aim to fix a broken screening system for high-risk patients.

With a newly published pediatric case study and a recent $50 million funding lifeline, Quoin Pharmaceuticals is racing to deliver the first approved therapy for Netherton Syndrome.

Margaret Mitchell explores how a German biotech's moss-grown protein could shift the paradigm in complement-mediated diseases from inhibition to restoration.

Equillium's Phase 1 trial of EQ504 in Australia signals a strategic shift in ulcerative colitis care, prioritizing targeted mucosal healing.

With Phase 3 enrollment complete, vTv Therapeutics aims to succeed where pharmaceutical giants failed in the quest for a Type 1 diabetes pill.

Pacira BioSciences taps Molteni Farmaceutici to navigate Europe’s fragmented market, trading direct control for a capital-efficient rollout of EXPAREL.

With new Canadian government funding, Vasomune Therapeutics is reformulating its vascular leak drug for the frontlines of military and civilian trauma.

New clinical data published in the Journal of Fungi reveals Moberg Pharma's MOB-015 overcomes terbinafine resistance, unlocking massive market potential.

As 20/20 BioLabs brings its needle-free, AI-powered cancer tests to the Maxim Growth Summit, the startup faces intense scrutiny over its financial runway.

PEI's $32M drug subsidy renewal isn't just about local healthcare—it's a critical financial prototype for Canada's looming national pharmacare rollout.

Astellas Pharma's real-world study uses medical-grade wearables to prove its non-hormonal menopause drug Veozah significantly reduces nighttime awakenings.

JCR Pharmaceuticals and Italfarmaco are teaming up to bring a revolutionary, brain-penetrating Hunter syndrome therapy to Western markets.

PolyPid has regained European rights to its promising infection-fighting drug. Now begins a high-stakes race to secure a partner before approval.

The NHS rollout of Tryngolza offers a monthly RNA-targeted lifeline for FCS patients, proving the practical value of execution in genetic lipid disorders.

As a critical FDA decision looms for its lead drug, Hansa Biopharma partners with Cradle to build a sustainable, AI-driven autoimmune discovery engine.

Dunbar Pharmaceuticals has launched the UK’s first plant-derived dronabinol oral spray, signaling a major shift in European biopharma infrastructure.

Targeted protein degradation is breaking out of oncology. Monte Rosa’s latest Phase 1 readout tests if molecular glues can solve residual heart disease risk.